HW-130

Primary objectives: To evaluate the safety and tolerability of HW130 in the treatment of patients with advanced malignant solid tumors who have failed standard treatment, and to explore the maximum tolerated dose (MTD) of HW130 and determine the recommended dose (RP2D) for Phase II clinical trials. Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of HW130; 2) To preliminarily evaluate the anti-tumor efficacy of HW130;